It marks J&J's first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.on Tuesday reported adjusted earnings and revenue that topped Wall Street's expectations, driven by a surge in sales in the company's medical devices and pharmaceutical business divisions.The drugmaker raised that revised outlook on Tuesday: J&J expects 2023 sales of $83.6 billion to $84 billion, compared to a previous guidance of $83.
Here's what J&J reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:Shares of J&J have dropped nearly 11% for the year, putting the company's market value at roughly $379 billion.The third-quarter results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based products were contaminated with the carcinogen asbestos, which caused ovarian cancer and several deaths.
Those products, including J&J's namesake baby powder, now fall under Kenvue. But J&J will assume all talc-related liabilities that arise in the U.S. and Canada. In 2021, J&J offloaded its talc liabilities into a new subsidiary, LTL Management, and immediately filed for Chapter 11 bankruptcy protections. But a federal bankruptcy judge in Julycelebrity deaths
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: NBCLA - 🏆 319. / 59 اقرأ أكثر »
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »